Endoron Medical, a Tel Aviv, Israel-based medtech company specializing in endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms, raised $10M in Series A funding.
The round was led by Sofinnova Partners, with participation from the European Innovation Council Fund (EIC Fund).
The company intends to use the funds to accelerate the clinical validation of its flagship product, the catheter-based EndoStapling solution Aortoseal, as it progresses through its Investigational Device Exemption (IDE) approved Early Feasibility Study (EFS).
Founded by Ronit Harpaz, Prof. Ron Karmeli, and Eyal Teichman, Endoron provides technologies for the endovascular repair of abdominal aortic aneurysms (AAA). It addresses challenges of sealing and securing endografts used in minimally invasive AAA repairs, particularly in complex procedures. Its stapling mechanism ensures complete sealing of endografts while securely anchoring them, preventing long-term migration and endoleaks, thereby reducing the need for highly invasive, high-mortality open surgeries.
FinSMEs
09/07/2024